Juniper Pharmaceuticals, Inc. Common Stock
JNP
JNP was delisted on the 13th of August, 2018.
47 hedge funds and large institutions have $51.2M invested in Juniper Pharmaceuticals, Inc. Common Stock in 2018 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 16 increasing their positions, 9 reducing their positions, and 4 closing their positions.
68,100% more call options, than puts
Call options by funds: $682K | Put options by funds: $1K
275% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 4
146% more capital invested
Capital invested by funds: $20.9M → $51.2M (+$30.4M)
78% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 9
31% more funds holding
Funds holding: 36 → 47 (+11)
6.34% more ownership
Funds ownership: 39.67% → 46.01% (+6.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIC
AWM Investment Company
New York
|
+$1.26M |
| 2 |
ACM
Ativo Capital Management
Chicago,
Illinois
|
+$1.05M |
| 3 |
Renaissance Technologies
New York
|
+$1.03M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$717K |
| 5 |
OAM
Oberweis Asset Management
Lisle,
Illinois
|
+$672K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KAM
Krensavage Asset Management
New York
|
-$901K |
| 2 |
BlackRock
New York
|
-$878K |
| 3 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
-$840K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$470K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$87.4K |
JNP Hedge Fund Activity: Q1 2018 in Review
47 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Juniper Pharmaceuticals, Inc. Common Stock (JNP) for Q1 2018, worth a combined $51.2M — up 146% from $20.9M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new JNP positions and 4 closed out — a net gain of 11 holders — while 16 added to existing stakes and 9 trimmed.
The largest buyer was AWM Investment Company, opening a new position worth an estimated $1.26M. The largest seller was Krensavage Asset Management, cutting an estimated $901K.
- 47 institutional investors held Juniper Pharmaceuticals, Inc. Common Stock (JNP) as of Q1 2018, up from 36 in Q4 2017.
- Funds reported $51.2M of Juniper Pharmaceuticals, Inc. Common Stock stock for Q1 2018, up 146% quarter-over-quarter.
- 15 funds opened new Juniper Pharmaceuticals, Inc. Common Stock positions in Q1 2018 and 4 closed out, a net change of +11 holders.
- The largest Juniper Pharmaceuticals, Inc. Common Stock buyer in Q1 2018 was AWM Investment Company, an estimated $1.26M added.
- The largest Juniper Pharmaceuticals, Inc. Common Stock seller in Q1 2018 was Krensavage Asset Management, an estimated $901K sold.
Based on aggregated 13F filings for Q1 2018.